Indication

Hypereosinophilic syndrome

Hypereosinophilic syndrome comprises a heterogeneous group of rare disorders characterized by marked, sustained overproduction of eosinophils in peripheral blood or tissues without identifiable secondary causes. Read more about Hypereosinophilic syndrome

31 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Hypereosinophilic syndrome therapies.

Showing 19–27 of 31 drugs

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AREVA PHARMACEU

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
GSMS, INC.

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
CHARTWELL RX LL

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AHP

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
AUROBINDO PHARM

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
ARMAS PHARMACEU

IMKELDI (imatinib mesylate)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
SHORLA PHARMA I

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
QUALLENT PHARMA

IMATINIB MESYLATE

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA·+11
BLUEPOINT/ONCOP
Filter & compare in the drug finder →Opens the drug finder with Hypereosinophilic syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hypereosinophilic syndrome.

Hypereosinophilic syndrome comprises a heterogeneous group of rare disorders characterized by marked, sustained overproduction of eosinophils in peripheral blood or tissues without identifiable secondary causes.

The condition occurs predominantly in adults, though it can manifest at any age.

Pathophysiologically, sustained hyperactivation and degranulation of eosinophils lead to cytotoxicity, local inflammation, and progressive tissue remodeling.

Clinical manifestations vary widely according to the pattern of tissue infiltration, frequently producing multiorgan dysfunction or damage across the dermatologic, cardiac, pulmonary, gastrointestinal, and central or peripheral nervous systems.

Personalize your experience

Follow Hypereosinophilic syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it